Dicerna Pharma (NASDAQ: DRNA) reported Q3 EPS of ($0.35), $0.10 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $1.55 million versus the consensus estimate of $1.7 million.

For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.